Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
19 March 2012 |
Main ID: |
EUCTR2006-004598-83-GB |
Date of registration:
|
24/10/2008 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
High dose immunoablation and autologous hematopoietic stem cell transplantation versus monthly intravenous pulse therapy cyclophosphamide in severe systemic sclerosis
( ‘ASTIS’-TRIAL: Autologous Stem Cell Transplantation International Scleroderma Trial)
- ASTIS
|
Scientific title:
|
High dose immunoablation and autologous hematopoietic stem cell transplantation versus monthly intravenous pulse therapy cyclophosphamide in severe systemic sclerosis
( ‘ASTIS’-TRIAL: Autologous Stem Cell Transplantation International Scleroderma Trial)
- ASTIS |
Date of first enrolment:
|
22/10/2008 |
Target sample size:
|
150 |
Recruitment status: |
Authorised-recruitment may be ongoing or finished |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-004598-83 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: no
Other: no
|
Phase:
|
|
|
Countries of recruitment
|
United Kingdom
| | | | | | | |
Contacts
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Age between 18 and 65 years.
2. Established diagnosis of systemic sclerosis according to ARA-criteria.
3. Diffuse scleroderma with disease duration either: a. less than or equal 2 years since development of first sign of skin thickening, plus modified Rodnan skin score greater than or equal 20, plus involvement of trunk plus ESR > 25 mm/1st hour and/or Hb < 11 g/dL, not explained by other causes than active scleroderma, or b. less than or equal 4 years since development of first sign of skin thickening, plus modified Rodnan skin score greater than or equal 15, plus major organ involvement (with documented evidence of onset or clinically significant worsening in the previous 6 months) as defined by either:
a) Respiratory involvement = DLCO and/or (F)VC less than or equal 80% (of predicted) and evidence of interstitial lung disease (chest X-ray and/or HR-CT scan and/or bronchoalveolar lavage and/or biopsy of the lungs) with clinically relevant obstructive disease and emphysema excluded.
b) Renal involvement = any of the following criteria: hypertension (two successive BP readings of either systolic greater than or equal 160 mm Hg or diastolic > 110 mm Hg, at least 12 hours apart), persistent urinalysis abnormalities (proteinuria, hematuria, casts), microangiopathic hemolytic anemia, new renal insufficiency (serum creatinine > upper limit of normal); non-scleroderma related causes (e.g. medication, infection etc.) must be reasonably excluded.
c) Cardiac involvement = any of the following criteria: reversible congestive heart failure, atrial or ventricular rhythm disturbances such as recurrent episodes of atrial fibrillation or flutter, recurrent atrial paroxysmal tachycardia or ventricular tachycardia, 2nd or 3rd degree AV-block, pericardial effusion; non-scleroderma related causes must have been reasonably excluded by an experienced cardiologist.
4. Written informed consent
Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria: 1. Pregnancy or unwillingness to use adequate contraception during study
2. Concomitant severe disease =
2.1 respiratory: mean PAP > 50 mmHg (by cardiac echo or right heart catheterization), DLCO < 40% predicted, respiratory failure as defined by the primary endpoint
2.2 renal: creatinine clearance < 40 ml/min (measured or estimated)
2.3 cardiac: clinical evidence of refractory congestive heart failure; LVEF < 45% by multigated radionuclide angiography (MUGA) or cardiac echo; chronic atrial fibrillation necessitating oral anticoagulation; uncontrolled ventricular arrhythmia; pericardial effusion with hemodynamic consequences as evaluated by an experienced echocardiographist
2.4 liver failure as defined by a sustained 3-fold increase in serum transaminase or bilirubin
2.5 psychiatric disorders including active drug or alcohol abuse
2.6 concurrent neoplasms or myelodysplasia
2.7 bone marrow insufficiency defined as leucocytopenia < 4.0 x 109/L, thrombocytopenia < 50 x 109/L, anemia < 8 gr/dL, CD4+ T lymphopenia < 200 x 106/L
2.8 uncontrolled hypertension
2.9 uncontrolled acute or chronic infection, including HIV, HTLV-1,2 positivity
3. Previous treatments with TLI, TBI or alkylating agents including cyclophosphamide (> 5 g i.v. cumulative, or > 3 months oral up to 2 mg/kg b.wt).
4. Significant exposure to bleomycin, tainted rapeseed oil, vinyl chloride, trichlorethylene or silica; eosinophilic myalgia syndrome; eosinophilic fasciitis.
5. Poor compliance of the patient as assessed by the referring physicians.
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Severe systemic sclerosis MedDRA version: 9.1
Level: LLT
Classification code 10042953
Term: Systemic sclerosis
|
Intervention(s)
|
Trade Name: Cyclophosphamide Product Name: Cyclophosphamide Pharmaceutical Form: Intravenous infusion INN or Proposed INN: CYCLOPHOSPHAMIDE CAS Number: 50180 Current Sponsor code: Cyclophosphamide Concentration unit: g gram(s) Concentration type: equal Concentration number: 28-
Trade Name: Neupogen Product Name: Filgrastim Pharmaceutical Form: Injection* INN or Proposed INN: FILGRASTIM CAS Number: 121181531 Concentration unit: µg/kg microgram(s)/kilogram Concentration type: equal Concentration number: 10-
Trade Name: Thymoglobuline Product Name: Thymoglobuline Product Code: rbATG Pharmaceutical Form: Intravenous infusion INN or Proposed INN: Anti-Thymocyte Globulin, Rabbit Other descriptive name: ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN FROM RABBITS Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal Concentration number: 2.5-
Trade Name: Solu-Medrone Product Name: Methylprednisolone Pharmaceutical Form: Intravenous infusion INN or Proposed INN: METHYLPREDNISOLONE CAS Number: 83432 Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal Concentration number: 1-
Trade Name: Cyclophosphamide Product Name: Cyclophosphamide Pharmaceutical Form: Intravenous infusion INN or Proposed INN: CYCLOPHOSPHAMIDE CAS Number: 50180 Concentration unit: mg/m2 milligram(s)/square meter Concentration type: equal Concentration number: 750-
Trade Name: Mesna Product Name: Mesna Pharmaceutical Form: Solution for injection INN or Proposed INN: MESNA CAS Number: 19767454 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400-
Trade Name: Mesna Product Name: Mesna Pharmaceutical Form: Solution for injection INN or Proposed INN: MESNA CAS Number: 19767454 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400-
|
Primary Outcome(s)
|
Main Objective: To evaluate the potential clinical benefit of high dose immunoablation and autologous stem cell transplantation in comparison to intravenous pulse therapy cyclophosphamide, with respect to:
- Survival and prevention of major organ failure (‘event-free survival’)
- Safety
- Impact on skin thickening, visceral involvement, functional status, and quality of life
|
Primary end point(s): The primary endpoint is event-free survival.
Event-free survival is defined as the time in days from the day of randomization until the occurrence of death due to any cause or the development of persistent1 major organ failure (heart, lung, kidney) defined as follows: • Heart: left ventricular ejection fraction < 30% by MUGA (or cardiac echo2)
• Lungs: respiratory failure = resting arterial oxygen tension (PaO2) < 8 kPa (< 60 mmHg) and/or resting arterial carbon dioxide tension (PaCO2) > 6.7 kPa (> 50 mmHg) without oxygen supply
• Kidney: need for renal replacement therapy
|
Secondary Objective: 1. To evaluate (in both treatment arms) whether disease activity correlates with immunological parameters, including immunopathology of skin, immune reconstitution, and autoantibodies.
2. To search for predictive factors (clinical and immunological) of response.
|
Source(s) of Monetary Support
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|